drug

lithium carbonate

MeSH D016651
as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Melbourne Health
1 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

1
Indicated Prevention of Psychotic Disorders With Low-dose Lithium
NCT00202306Phase 4Completed

KOLs & investigators

1
Gregor E Berger, MDKOL score 5

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Melbourne Health
company
trial
Indicated Prevention of Psychotic Disorders With Low-dose Lithium
PHASE4
trial
indication
Schizophrenia
indication
Bipolar Disorder
indication
Schizophrenia
indication
Psychotic Disorders
indication
KOL
Gregor E Berger, MD
KOL score 5
person